BioInvent International AB (publ) (0H22.L)

44,54 0,00 (0,00%) Alla chiusura: 05:13PM BST

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 111

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Martin Welschof Ph.D.	President & CEO	5,06M	N/D	1961
Mr. Stefan Ericsson M.B.A.	Chief Financial Officer	N/D	N/D	1963
Ms. Marie Moores M.Sc., R.G.N.	Chief Operating Officer	N/D	N/D	N/D
Mr. Kristoffer Rudenholm Hansson	Senior Vice President of Technical Operations	N/D	N/D	1974
Mr. Björn Frendéus	Chief Scientific Officer	2,35M	N/D	1973
Ms. Cecilia Hofvander	Senior Director of Investor Relations	N/D	N/D	1967
Dr. Andres McAllister	Chief Medical Officer	N/D	N/D	1956
Ms. Ingrid Teige	Head of Preclinical Research	N/D	N/D	N/D
Ms. Sylvie Ryckebusch	Chief Business Officer	N/D	N/D	N/D
Dr. Ingunn Munch Lindvig	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in SEK.

Descrizione

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.

Governance aziendale

L'ISS Governance QualityScore di BioInvent International AB (publ) al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.